Table 3.

Urticarial rash incidence; red cells denote TOL101 dose at time of rash

Treatment Group	Patient	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Dose 8
0.28 mg	06-001
	08-001
1.4 mg	02-001
	04-001
7.0 mg	02-002
	04-002
14.0 mg	05-001
	08-002
28.0 mg	01-001
	04-003
	07-001
	03-001
	07-0031
	07-004
32.0 mg	03-0021
	08-004
	12-0011
	07-005
42mg	06-0021
	07-002
	04-004
	08-003
Escalation Group 1 14-42mg	07-006	14mg	21mg	28mg	42mg	42mg	42mg
	07-007	14mg	21mg	28mg	42mg	42mg	42mg
	07-008	14mg	21mg	28mg	42mg	42mg	42mg
	08-0051	14mg	21mg	28mg	42mg	42mg	42mg
	07-009	14mg	21mg	28mg	42mg	42mg	42mg
	02-003	14mg	21mg	28mg	42mg	42mg	42mg
Escalation Group 2 21-42mg	07-010	21mg	28mg	42mg	42mg	42mg	42mg	42mg	42mg
	07-011	21mg	28mg	42mg	42mg	42mg	42mg	42mg	42mg
	07-012	21mg	28mg	42mg	42mg	42mg
	07-013	21mg	28mg	42mg	42mg	42mg
	02-004	21mg	28mg	42mg	42mg	42mg
	03-003	21mg	28mg	42mg	42mg	42mg
	03-004	21mg	28mg	42mg	42mg	42mg

¹Patients that had biopsy-confirmed acute rejection